Common Questions

Is Moderna making an H5N1 bird flu vaccine?

Yes. Moderna began the first Phase 3 trial of an mRNA H5N1 vaccine candidate in April 2026, backed by CEPI, making it the furthest-advanced H5N1 mRNA vaccine in clinical development.Source: CEPI

How quickly can Moderna update its mRNA vaccine for a new pandemic strain?

Moderna's mRNA platform can update its vaccine template in weeks once the target antigen sequence is known, compared to months for egg-based or protein-subunit conventional vaccines.

What is Moderna's mRNA-1273 vaccine and when was it approved?

mRNA-1273 (Spikevax) is Moderna's COVID-19 vaccine, authorised in late 2020. It was the first large-scale demonstration that mRNA vaccines could be developed, manufactured and deployed at population scale.

Background

Moderna is a US biotechnology company founded in 2010 in Cambridge, Massachusetts, specialising in messenger RNA (mRNA) therapeutics and vaccines. It became one of the two companies (alongside Pfizer-BioNTech) to bring an authorised mRNA COVID-19 vaccine to market in late 2020, validating the mRNA platform at population scale for the first time. Moderna's approach uses synthetic mRNA sequences to instruct cells to produce a target protein, triggering an immune response without using live or attenuated virus. The platform's key pandemic-preparedness advantage is speed: once a pathogen's target antigen sequence is known, Moderna can update its mRNA vaccine template in weeks rather than the months required by egg-based or protein-subunit approaches. The company is publicly traded (Nasdaq: mRNA).

Moderna is now the central mRNA partner across two of CEPI's most urgent programmes. It began the first Phase 3 trial of an mRNA-based H5N1 vaccine candidate (mRNA-1018) in April 2026, after CEPI rescued the trial with $54.3 million when the US Department of Health and Human Services pulled its funding. This is the furthest any H5N1 mRNA candidate has reached in clinical development globally. On 1 June 2026 CEPI added a $50 million commitment for Moderna to develop an mRNA candidate against Bundibugyo ebolavirus through Phase 1, the most advanced mRNA bet on a filovirus outside Zaire ebolavirus. On 9 June 2026, CEPI separately funded a fourth Bundibugyo vaccine candidate, bringing the total portfolio to over $63.7 million across four candidates and three platforms. GAVI has committed contingent procurement guarantees against any candidate that reaches emergency authorisation.

More questions

Why does the H5N1 Phase 3 trial matter for pandemic preparedness?

A successful trial establishes a regulatory-approved H5N1 mRNA manufacturing pathway. If a pandemic H5N1 strain emerges, Moderna can update the antigen and roll out a strain-matched vaccine FAR faster than starting from scratch.Source: CEPI

What is Moderna's H5N1 vaccine and how far along is it?

Moderna began dosing the first participants in a Phase 3 H5N1 mRNA trial (mRNA-1018) on 21 April 2026, after CEPI stepped in with $54.3m when US government funding was withdrawn. This is the furthest any H5N1 mRNA candidate has progressed.Source: CEPI

Is Moderna developing an Ebola vaccine?

Yes. CEPI committed $50m to Moderna on 1 June 2026 to develop an mRNA vaccine candidate against Bundibugyo ebolavirus through Phase 1, the first major mRNA investment against a non-Zaire Ebola species.Source: CEPI

Why did the US government stop funding Moderna's H5N1 trial?

The US Department of Health and Human Services withdrew funding under the Trump administration's cuts to pandemic preparedness programmes in early 2026. CEPI stepped in as the sole sponsor.Source: CEPI

How does Moderna's mRNA platform help with pandemic preparedness?

Once a pathogen's target antigen is sequenced, Moderna can design and manufacture a candidate vaccine in weeks rather than the months required by egg-based or protein-subunit approaches, directly enabling CEPI's 100 Days Mission.

Source Material

Moderna — Official Website Moderna

How the World Sees Them

China

China's mRNA vaccine development lagged during COVID-19; a US-led H5N1 mRNA approval would reinforce Western platform dominance in the next pandemic cycle.

United States

Moderna is a US company; the H5N1 trial has direct national security implications given active dairy-cattle infections in Idaho and the dairy-worker exposure pathway.

European Union

EMA will review Phase 3 data; the EU's HERA stockpile strategy anticipates a pre-pandemic mRNA H5N1 allocation similar to the COVID-19 advance-purchase agreements.

Low and middle-income countries

CEPI's involvement aims to ensure equitable access to any resulting H5N1 vaccine; COVID-19 demonstrated that mRNA vaccines reached wealthy nations months before poorer ones without structured procurement.